Cargando…

Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence

Cefiderocol is a novel synthetic siderophore-conjugated antibiotic that hijacks the bacterial iron transport systems facilitating drug entry into cells, achieving high periplasmic concentrations. This systematic review analyzed the currently available literature on cefiderocol. It summarized in vitr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Chuanhai, Yang, Deqing, Wang, Yifan, Ni, Wentao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039133/ https://www.ncbi.nlm.nih.gov/pubmed/35496290 http://dx.doi.org/10.3389/fphar.2022.896971

Ejemplares similares

Erratum: Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence
por: Frontiers Production Office,
Publicado: (2022)

Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria
por: Wang, Yifan, et al.
Publicado: (2022)

Cefiderocol, a new antibiotic against multidrug-resistant Gram-negative bacteria
por: Silva, José Tiago, et al.
Publicado: (2021)

In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria
por: Ito, Akinobu, et al.
Publicado: (2017)

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria
por: Mushtaq, Shazad, et al.
Publicado: (2020)

Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects
por: Saisho, Yutaka, et al.
Publicado: (2018)

Cefiderocol Retains Antibiofilm Activity in Multidrug-Resistant Gram-Negative Pathogens
por: Pybus, Christine A., et al.
Publicado: (2021)

Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms
por: Wu, Janet Y., et al.
Publicado: (2020)

Activities of Cefiderocol with Simulated Human Plasma Concentrations against Carbapenem-Resistant Gram-Negative Bacilli in an In Vitro Chemostat Model
por: Matsumoto, Shuhei, et al.
Publicado: (2020)

Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data
por: Giacobbe, Daniele Roberto, et al.
Publicado: (2020)

2811. Real-World Experience Utilizing Cefiderocol for Serious Multidrug Resistant Gram-Negative Infections
por: Teran, Nicholas S, et al.
Publicado: (2023)

Performance evaluation of the UMIC(®) Cefiderocol to determine MIC in Gram-negative bacteria
por: Dortet, Laurent, et al.
Publicado: (2023)

640. A Retrospective Assessment of the Effects of Cefiderocol in Patients with Multidrug-resistant Gram-negative Bacterial Infections
por: Sajib, Monirul I, et al.
Publicado: (2022)

Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics
por: Matsumoto, Shuhei, et al.
Publicado: (2017)

Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria
por: Watkins, Richard R., et al.
Publicado: (2019)

Stewardship of Antibiotics for Multidrug-Resistant Gram-Negative Bacteria
por: Giacobbe, Daniele Roberto, et al.
Publicado: (2020)

The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol
por: Taheri, Yasaman, et al.
Publicado: (2021)

Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: an Italian multicentre real-life experience
por: Piccica, Matteo, et al.
Publicado: (2023)

Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria
por: Tängdén, Thomas
Publicado: (2014)

Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia
por: Cillóniz, Catia, et al.
Publicado: (2019)

Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia
por: Cillóniz, C., et al.
Publicado: (2018)

In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
por: Yamano, Yoshinori
Publicado: (2019)

Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model
por: Stainton, Sean M., et al.
Publicado: (2019)

Machine Learning and Multidrug-Resistant Gram-Negative Bacteria: An Interesting Combination for Current and Future Research
por: Giacobbe, Daniele Roberto, et al.
Publicado: (2020)

Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections
por: Gavaghan, Victoria, et al.
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic Based Breakpoints of Polymyxin B for Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Pathogens
por: Bian, Xingchen, et al.
Publicado: (2022)

Compartmentalization of lipid peroxidation in sepsis by multidrug-resistant gram-negative bacteria: experimental and clinical evidence
por: Toufekoula, Chryssoula, et al.
Publicado: (2013)

Resensitizing multidrug-resistant Gram-negative bacteria to carbapenems and colistin using disulfiram
por: Chen, Chen, et al.
Publicado: (2023)

Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections
por: Syed, Yahiya Y.
Publicado: (2021)

P35 Heteroresistance to cefiderocol in clinical Gram-negative isolates
por: Watson, Celeste, et al.
Publicado: (2023)

Evaluation of a Library of FDA-Approved Drugs for Their Ability To Potentiate Antibiotics against Multidrug-Resistant Gram-Negative Pathogens
por: Hind, Charlotte K., et al.
Publicado: (2019)

Feasibility of Continuous Infusion of Cefiderocol in Conjunction with the Establishment of Therapeutic Drug Monitoring in Patients with Extensively Drug-Resistant Gram-Negative Bacteria
por: Prinz, Carolin, et al.
Publicado: (2023)

New Multidrug Efflux Inhibitors for Gram-Negative Bacteria
por: Marshall, Robert L., et al.
Publicado: (2020)

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
por: Hackel, Meredith A., et al.
Publicado: (2018)

Population Pharmacokinetics and Limited Sampling Strategy for Therapeutic Drug Monitoring of Polymyxin B in Chinese Patients With Multidrug-Resistant Gram-Negative Bacterial Infections
por: Wang, Peile, et al.
Publicado: (2020)

Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms
por: Bianco, Gabriele, et al.
Publicado: (2022)

Antibiotic resistance: What is so special about multidrug-resistant Gram-negative bacteria?
por: Exner, Martin, et al.
Publicado: (2017)

Squalamine: An Appropriate Strategy against the Emergence of Multidrug Resistant Gram-Negative Bacteria?
por: Salmi, Chanaz, et al.
Publicado: (2008)

Parenteral colistin for the treatment of severe infections by multidrug-resistant Gram-negative bacteria
por: Grion, C, et al.
Publicado: (2013)

Epidemiology and molecular characterization of multidrug-resistant Gram-negative bacteria in Southeast Asia
por: Suwantarat, Nuntra, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kkv3l6bv0t8f33be2g5c5t02q6